Drug Trial Radar · NCT04905914
Study Of ATRN-119 In Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jan 9, 2023
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- Aprea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
ATRN-119Drug
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statisticsTime frame: Day 1 to Day 28
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut
University Hospitals, Cleveland Medical Center
Cleveland, Ohio
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Mary Crowley Cancer Research
Dallas, Texas
NEXT- Oncology Dallas
Irving, Texas
NEXT Oncology- San Antonio
San Antonio, Texas
NEXT Oncology- Virginia
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.